X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cadila Healthcare with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ACTAVIS (US) - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CADILA HEALTHCARE   ACTAVIS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
ACTAVIS
Dec-14
CADILA HEALTHCARE/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs46018,561-   
Low Rs30511,322-   
Sales per share (Unadj.) Rs92.13,342.4-  
Earnings per share (Unadj.) Rs14.8-417.1-  
Cash flow per share (Unadj.) Rs18.5306.7-  
Dividends per share (Unadj.) Rs3.200-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs68.07,249.5-  
Shares outstanding (eoy) m1,023.74265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.5 92.9%   
Avg P/E ratio x25.8-35.8 -72.1%  
P/CF ratio (eoy) x20.748.7 42.5%  
Price / Book Value ratio x5.62.1 273.0%  
Dividend payout %21.60-   
Avg Mkt Cap Rs m391,5813,972,967 9.9%   
No. of employees `00016.921.6 78.0%   
Total wages/salary Rs m15,0020-   
Avg. sales/employee Rs Th5,594.541,145.3 13.6%   
Avg. wages/employee Rs Th890.10-   
Avg. net profit/employee Rs Th899.9-5,134.5 -17.5%   
INCOME DATA
Net Sales Rs m94,295888,738 10.6%  
Other income Rs m1,286-2,218 -58.0%   
Total revenues Rs m95,581886,520 10.8%   
Gross profit Rs m19,036114,171 16.7%  
Depreciation Rs m3,750192,444 1.9%   
Interest Rs m45028,032 1.6%   
Profit before tax Rs m16,122-108,524 -14.9%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3-7,961 0.0%   
Tax Rs m1,289-5,579 -23.1%   
Profit after tax Rs m15,168-110,905 -13.7%  
Gross profit margin %20.212.8 157.1%  
Effective tax rate %8.05.1 155.5%   
Net profit margin %16.1-12.5 -128.9%  
BALANCE SHEET DATA
Current assets Rs m60,223468,251 12.9%   
Current liabilities Rs m53,058341,493 15.5%   
Net working cap to sales %7.614.3 53.3%  
Current ratio x1.11.4 82.8%  
Inventory Days Days7058 120.4%  
Debtors Days Days8866 133.0%  
Net fixed assets Rs m72,984108,524 67.3%   
Share capital Rs m1,0240-   
"Free" reserves Rs m68,5760-   
Net worth Rs m69,6001,927,641 3.6%   
Long term debt Rs m24,6841,010,122 2.4%   
Total assets Rs m152,2073,532,732 4.3%  
Interest coverage x36.8-2.9 -1,282.6%   
Debt to equity ratio x0.40.5 67.7%  
Sales to assets ratio x0.60.3 246.3%   
Return on assets %10.3-2.3 -437.4%  
Return on equity %21.8-5.8 -378.8%  
Return on capital %17.9-3.0 -595.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,4060-   
CASH FLOW
From Operations Rs m13,495152,614 8.8%  
From Investments Rs m-29,103-365,416 8.0%  
From Financial Activity Rs m23,158205,311 11.3%  
Net Cashflow Rs m7,556-7,491 -100.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.04 Rs / USD

Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare CADILA HEALTHCARE With: J.B.CHEMICALS  ELDER PHARMA  ALEMBIC LTD  GSK PHARMA  NOVARTIS  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views On News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jun 18, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS